2020
DOI: 10.3389/fimmu.2020.00909
|View full text |Cite
|
Sign up to set email alerts
|

Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines

Abstract: Adenoviral vectors are a safe and potently immunogenic vaccine delivery platform. Non-replicating Ad vectors possess several attributes which make them attractive vaccines for infectious disease, including their capacity for high titer growth, ease of manipulation, safety, and immunogenicity in clinical studies, as well as their compatibility with clinical manufacturing and thermo-stabilization procedures. In general, Ad vectors are immunogenic vaccines, which elicit robust transgene antigen-specific cellular … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

6
141
1
3

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 114 publications
(164 citation statements)
references
References 183 publications
(185 reference statements)
6
141
1
3
Order By: Relevance
“…Positive staining was patchy, as would be expected for non-uniform transduction of the lung with the Ad-hACE2 vector. Transduction of epithelial cells, alveolar macrophages and endothelial cells is consistent with the known tropism and target cells for HAdV-C5 based vectors in mice [ 33 , 38 , 39 ]. Although the lowest dose of Ad-hACE2 (7.5×10 7 PFU) appeared to yield a similar distribution of transduction in the lung to the highest dose (2.5×10 8 PFU), the intensity of staining appeared to be dose-dependent with more intense brown staining for hACE2 in the highest dose of Ad-hACE2 (2.5×10 8 PFU).…”
Section: Resultsmentioning
confidence: 68%
See 1 more Smart Citation
“…Positive staining was patchy, as would be expected for non-uniform transduction of the lung with the Ad-hACE2 vector. Transduction of epithelial cells, alveolar macrophages and endothelial cells is consistent with the known tropism and target cells for HAdV-C5 based vectors in mice [ 33 , 38 , 39 ]. Although the lowest dose of Ad-hACE2 (7.5×10 7 PFU) appeared to yield a similar distribution of transduction in the lung to the highest dose (2.5×10 8 PFU), the intensity of staining appeared to be dose-dependent with more intense brown staining for hACE2 in the highest dose of Ad-hACE2 (2.5×10 8 PFU).…”
Section: Resultsmentioning
confidence: 68%
“…Recombinant Ad vectors can be used to transduce a wide-range of cell types, both in vitro and in vivo, and are well-established to facilitate sustained transgene expression when used as a delivery vector (33). Prior studies have demonstrated that Ad-mediated delivery of a functional viral entry receptor into mice, such as the human dipeptidyl peptidase 4 (hDPP4) receptor for Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV), can render them permissive to infection with human viruses, which are otherwise unable to support viral entry using the murine receptor homolog (26,34).…”
Section: Validation Of Adenovirus-mediated Delivery Of Hace2mentioning
confidence: 99%
“…Some studies using Ad-hACE2 have used IFNAR -/mice, or have blocked IFNAR1 using α-IFNAR1 mAbs, demonstrating that a lack of intact type I IFN response in mice resulted in greater weight loss and exacerbated lung pathology upon SARS-CoV-2 infection (15,33), and concluding that IFN may have protective effects against SARS-CoV-2. However, this should be validated in an additional model for hACE2, as there is evidence that blockade of Type I IFN can affect transgene expression from nonreplicating Ad vectors and T cell responses to the transgene/vector, which could confound results (39,62).…”
Section: Discussionmentioning
confidence: 99%
“…Recombinant Ad vectors can be used to transduce a wide-range of cell types, both in vitro and in vivo, and are well-established to facilitate sustained transgene expression when used as a delivery vector (39)(40)(41).…”
Section: Validation Of Adenovirus-mediated Delivery Of Hace2mentioning
confidence: 99%
“…The use of virus-based vaccines has been studied for many years, although until now only one viral-vector vaccine has been approved for use in humans, the rVSV-ZEBOV-GP indicated against Ebola [ 124 ]. Nevertheless, some of them are in the final steps of the clinical trials [ 125 ]. Despite all the advantages that this kind of vaccines have, they still have some disadvantages such as the pre-existing immunity that can be found against the most common viral-vectors (poxvirus and adenovirus), which might decrease the efficacy of the vaccine [ 126 ], or the lack of proper animal models [ 127 ].…”
Section: Discussionmentioning
confidence: 99%